Alpha Teknova (TKNO) investor relations material

Company overview and growth milestones

• Leading provider of critical reagents for therapy and diagnostics, with a 30-year history and five years as a public company.

• Expanded from catalog products to custom capabilities, now serving over 3,000 customers annually.

• Achieved ISO 13485 certification in 2018, enabling entry into GMP-grade clinical markets.

• Private equity investment in 2019 and IPO in 2021 fueled infrastructure and leadership expansion.

• Maintained expense discipline post-IPO, with recent revenue growth and raised annual guidance to $45–$47 million.

Financial performance and outlook

• Q2 revenue reached a record $12.2 million, with 18% growth and improved adjusted EBITDA and cash use.

• Guidance for 2026 cash use lowered to less than $8 million; adjusted EBITDA positive expected in 2027 at $52–$57 million revenue.

• Cash flow positive projected shortly after EBITDA breakeven, with sufficient capital to execute organic strategy.

• High fixed cost base enables strong operating leverage and margin expansion as revenue grows.

• Current capacity supports up to $200 million in revenue, minimizing need for near-term facility investment.

Product portfolio and market segmentation

• Offers agar plates, liquid microbial culture media, and molecular biology reagents in various formats.

• Biopharma is the largest end market (50%), followed by life science tools/diagnostics (30%) and other markets (15%).

• Revenue split: 75% Lab Essentials (catalog, research-grade), 20% Clinical Solutions (custom, GMP-grade).

• Customers buying GMP products generate 44x more revenue than catalog-only customers.

• Custom and catalog businesses together enable flexible production and inventory management.